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Objectives: Dobutamine and milrinone are commonly used after 
open-heart surgery to prevent or treat low cardiac output syn-
drome. We sought to compare efficacy and safety of these drugs 
in pediatric patients.
Design: Prospective, single-center, double-blinded, randomized 
clinical pilot study.
Setting: Tertiary-care university children’s hospital postoperative 
pediatric cardiac ICU.
Patients: After written consent, 50 consecutive patients (age, 
0.2–14.2 yr; median, 1.2 yr) undergoing open-heart surgery for 
congenital malformations were included.
Interventions: After cardiopulmonary bypass, a continuous infu-
sion of either dobutamine or milrinone was administered for the 
first 36 postoperative hours. Maximum dose: dobutamine 6 µg/
kg/min, milrinone 0.75 µg/kg/min.
Measurements and Main Results: There were no significant differ-
ences in demographic data, complexity of surgery, and intraopera-
tive characteristics between the two study groups (dobutamine vs 
milrinone). Efficacy was defined as need for additional vasoactive 
support, which did not differ between groups (dobutamine 61% 
vs milrinone 67%; p = 0.71). Sodium nitroprusside was used 
more often in the dobutamine group (42% vs 13%; p = 0.019). 
Systolic blood pressure showed a trend toward higher values in 
the dobutamine group, whereas both drugs increased heart rate 
early postoperatively. Echocardiography demonstrated a consis-
tently good cardiac function in both groups. Central venous oxy-
gen saturation, serum lactate levels, urine output, time to chest 
tube removal, length of mechanical ventilation, ICU, and hospital 
stay were similar in both groups. Both drugs were well tolerated, 
no serious adverse events occurred.
Conclusions: Dobutamine and milrinone are safe, well tolerated, 
and equally effective in prevention of low cardiac output syndrome 
after pediatric cardiac surgery. The hemodynamic response of the 
two drugs is comparable. In uncomplicated cases, a trend toward 
the more cost-saving dobutamine might be anticipated; however, 
milrinone demonstrated a trend toward higher efficacy in afterload 
reduction. (Pediatr Crit Care Med 2018; XX:00–00)
Key Words: congenital heart disease; dobutamine; low cardiac 
output; milrinone; pediatric cardiac surgery; postoperative cardiac 
intensive care
Low cardiac output syndrome (LCOS) is frequent in infants and children after surgery for congenital heart defects and occurs typically 6–18 hours post surgery (1). It postpones 
recovery and contributes to morbidity and mortality (1, 2). IV 
inotropic agents and vasodilators are routinely used in the post-
operative care for prevention and/or therapy of a LCOS (2–5).
Dobutamine is a synthetic direct-acting β1- and β2-
adrenergic receptor agonist with positive inotropic and mild DOI: 10.1097/PCC.0000000000001533
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chronotropic effects (6). Furthermore, it induces mild vasodi-
lation of the pulmonary and systemic vascular bed (7, 8). It 
has a rapid onset of action, a short half-life and its infusion 
rate is positively correlated to plasma concentrations (9). 
Dobutamine is used in clinical practice since 1975, and its 
pharmacokinetics have been studied in children (9, 10).
Milrinone is a selective inhibitor of the type III phosphodi-
esterase. It acts as a positive inotropic agent, reduces systemic 
and pulmonary vascular resistance, and enhances lusitropy 
with minimal increase in myocardial oxygen consumption 
(3, 7, 11–13). Milrinone is used in clinical practice since the 
early 1990s (7), and it is nowadays the most frequently used 
drug to prevent postoperative LCOS in children after cardiac 
surgery in Europe (5). In the postoperative care of children 
and neonates after open-heart surgery, milrinone has proved 
to be safe and shows an acute beneficial effect on hemodynam-
ics: it improves cardiac index, decreases filling pressures, and 
decreases pulmonary vascular resistance (3, 13). It has also 
been shown that milrinone reduces the relative risk of a post-
operative LCOS by as much as 64% (Primacorp [2]) and that 
there is a beneficial effect in optimization of cardiovascular 
function in the acute setting in the pediatric age group (14).
In adults, dobutamine and milrinone resulted in a similar 
significant and sustained increase in cardiac index, and both 
drugs were effective in improving the general hemodynamic 
variables in postsurgical cardiac patients (6, 15).
In our institution as well as in other European institutions 
(5), milrinone is the drug of first choice for prevention and ther-
apy of postoperative LCOS in the pediatric age group. However, 
some institutions prefer among others the considerably less 
expensive dobutamine for the same indication. Overall, there 
is marked variability in various preventive drug therapies, with 
only sparse evidence available, and the decision to use one or the 
other drug is mostly based purely on institutional preference (5).
Our hypothesis is that dobutamine and milrinone are equal 
for the prevention of a postoperative LCOS. With this study, 
we compared efficacy and side effects of dobutamine and mil-
rinone in children during the first postoperative period after 
open-heart surgery.
METHODS
Study Design and Population
We conducted a single-center, prospective, double-blinded, 
randomized trial with patients undergoing cardiac surgery for 
congenital heart defects at the University Children’s Hospital 
Zurich, Switzerland. Written informed consent was obtained. 
The study was approved by the local ethical committee.
All infants and children older than 6 weeks of age undergo-
ing cardiac surgery on cardiopulmonary bypass (CPB) with a 
risk of postoperative LCOS based on the intracardiac anatomy 
and the performed surgery and in whom routine administra-
tion of postoperative inotropic support was anticipated were 
included into the study.
Patients with a body weight below 3 kg or above 35 kg, 
with significant postoperative left ventricular outflow tract 
obstruction or the need of extracorporeal membrane oxygen-
ation, were excluded from the study.
Interventions
Patients were randomized into two groups receiving an infusion 
of either dobutamine (Dobutrex; Teva Pharma AG, Basel, Swit-
zerland) or milrinone (Corotrop; Sanofi-Aventis SA, Vernier, 
Switzerland) for the first 36 hours postoperatively in a blinded 
fashion. The anesthetist started the study drug with an IV 
bolus of 50 µg/kg (maximum 1 mg) milrinone or sodium chlo-
ride 0.9%, respectively, over 15 minutes. Then, a continuous 
infusion (1 mL/hr) of the study drug was started. Upon arrival 
in the ICU, the continuous infusion was gradually increased 
to 2 mL/hr at 4 hours post arrival on ICU resulting in a target 
dose of 6 µg/kg/min dobutamine and 0.75 µg/kg/min milri-
none, respectively, which remained unchanged until 24 hours 
after arrival on ICU. Any other drug, for example, adrenaline, 
noradrenaline, or sodium nitroprusside, could be added to the 
study drug if indicated. The decision to initiate an additional 
drug was taken by the attending intensivist according to his/her 
individual clinical judgement and a combination of variables 
describing a LCOS (blood pressure lower than the age-related 
normal values, central venous oxygen saturation [Scvo
2
] 
value < 30% of the arterial saturation, diuresis < 1 mL/kg/hr, 
peripheral temperature < 32°C, serum lactate > 3 mmol/L). 
After 24 hours, the study drug was tapered down to 1.5 mL/hr, 
at 30 hours to 1 mL/hr, and at 36 hours it was stopped. In 
patients with persisting heart failure, a new continuous infu-
sion of milrinone was started in a nonblinded fashion.
Objectives
To analyze the efficacy of the study medications, we deter-
mined as primary endpoint the occurrence of LCOS in each 
study group. As measurement, we chose the additional amount 
of vasoactive support within the first 48 hours postopera-
tively. This was assessed by comparing the number of patients 
who needed supplementary vasoactive support (adrenaline, 
noradrenaline, or sodium nitroprusside) in addition to the 
standardized application of the study drugs dobutamine or mil-
rinone. Dobutamine and milrinone were not allowed as addi-
tional drugs during the continuous infusion of the study drug.
As secondary outcomes, the following variables were 
assessed: blood pressure; heart rate; diuresis; respiratory rate; 
Fio
2
; peripheral circulation (capillary refill time, peripheral tem-
perature); central to peripheral temperature gradient; central 
venous So
2
 and serum lactate; myocardial fractional shortening 
and ejection fraction at repeated echocardiographic evaluations; 
total duration of mechanical ventilation, inotropic support, and 
chest drainages; and length of ICU and hospital stay. The occur-
rence of adverse events was registered, and deaths were assessed 
up to 28 days
Randomization
The randomization was stratified by weight to ensure a balance 
across the study groups. (group I: 3–10 kg, group II: > 10 to 
24 kg, group III: > 24 to 35 kg).
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Eligible patients were randomly assigned to study groups 
in a 1:1 ratio (dobutamine and milrinone groups). Stratified 
randomization was accomplished using the minimization 
approach with biased coin assignment. Investigators, staff, and 
participants were blinded to the assigned group until after the 
end of the study.
Study Procedures and Data Collection
All invasive and noninvasive procedures were part of the stan-
dard treatment plan of our hospital. Hemodynamic monitor-
ing consisted of central venous and peripheral arterial catheter 
for continuous invasive pressure monitoring in all patients. 
Skin and rectal temperatures were measured continuously. 
Heart rate was constantly monitored with a five-leads elec-
trocardiogram (ECG) and blood oxygen saturation with a 
continuous pulse oximeter. All patients were postoperatively 
mechanically ventilated with ventilation and weaning strat-
egies according to the institutional standards. The central 
venous So
2
 was obtained from central venous catheter, pH, 
arterial So
2
, Pao
2
, Paco
2
, base excess, lactate levels, hemoglobin, 
electrolytes, glucose, creatinine, troponin, creatine kinase, and 
creatinine kinase-MB from the arterial catheter. Pericardial, 
mediastinal, and pleural chest drains were each removed when 
draining less than 0.5 mL/kg/hr. Urine output was recorded.
Data collection of invasive and noninvasive monitoring and 
ventilation was performed at arrival on ICU (time = 0) and 
every 4 hours thereafter for 48 hours. Blood tests were recorded 
every 8 hours. Echocardiography and 12-leads ECG were per-
formed prior to the operation and three times afterwards: at 
2–6, 24–30, and 48–54 hours after arrival on the ICU.
Statistic Analysis
Data are presented as frequencies, mean ± sd, or median and 
range as appropriate. Qualitative data are expressed as absolute 
numbers and percentage. Statistical significance is defined by p 
values of less than 0.05. For the primary endpoint, categorical 
variables are described as numbers (n) and percentages, then 
the two groups were compared using the chi-square test.
Secondary endpoints were visually examined for extreme 
observations and were analyzed by comparing the trend of 
each variable over the first postoperative 48 hours using vari-
ous graphs and student t tests where appropriate.
Single ventricle patients were compared with patients with-
out single ventricles in their age group with the Mann-Whitney 
U test.
Since this study was designed as a pilot study, no power cal-
culation was performed.
All calculations were done using SPSS for Windows XP ver-
sion 22 (SPSS 22.0.0.0; IBM Corp., Armonk, NY)
RESULTS
A total of 96 patients were assessed for eligibility. Fifty indi-
viduals were eventually enrolled and randomized, 26 were allo-
cated to the dobutamine, and 24 to the milrinone group.
The median age of the analyzed patients was 1.2 years (0.2–
14.2 yr), the median weight 8.6 kg (3.4–35.5 kg). Enrollment 
characteristics and distribution of patients into subgroups are 
shown in Figure 1. Infants belonging to subgroup I were repre-
sented with 26 patients (52%). There were no differences between 
the two study groups (dobutamine vs milrinone) in demographic 
data, complexity of surgery, and intraoperative characteristics 
(Table 1). In subgroup II, four children had single ventricles: 
three of the milrinone and one of the dobutamine group.
The need for additional vasoactive support due to the occur-
rence of a LCOS within the first 48 hours postoperatively, which 
was the primary objective of the study, did not differ between 
the two study groups, nor between the subgroups. It affected 
16 patients of each group (61% in the dobutamine vs 67% in 
the milrinone group; p = 0.71). The duration of additional 
vasoactive support was also equal in the two groups (30 ± 20 
vs 28 ± 22 hr; p = 0.37), also independently of the body weight. 
In the dobutamine group, significantly more patients needed 
additional afterload reduction with sodium nitroprusside: 11 
patients (42%) versus three patients (13%), p value equal to 
0.019. None of the patients with single ventricle needed sodium 
nitroprusside. The remaining vasoactiva were distributed as fol-
lows (some patients needed > one additional drug): adrenaline 
was necessary in six patients of the dobutamine and in nine of 
the milrinone group, noradrenaline in three of the dobutamine 
and five of the milrinone, and after completing the study drug, 
milrinone was started in three patients of each group.
There was no difference between the two groups (dobu-
tamine vs milrinone) in length of mechanical ventilation: 
7 hours (0–50 hr) versus 8 hours (1–78 hr), p value equal 
to 0.069, length of ICU stay: 2 days (2–10 d) versus 3 days 
(2–7 d), p value equal to 0.55, and length of hospital stay: 10 
days (7–69 d) versus 14 days (8–78 d), p value equal to 0.18. 
Comparing the subgroups, time to extubation was signifi-
cantly shorter in the dobutamine group I (patients ≤ 10 kg) 
compared with that in the corresponding milrinone group: 
median 19.2 hours (11.3–22.9 hr) versus 32.5 hours (19.8–
56.3 hr), p value equal to 0.03.
Figure 1. Flow chart of enrollment. Numbers indicate number of patients 
in each group
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Overall, there was no clinically significant difference in 
all measured hemodynamic variables between the two study 
groups. Furthermore, no significant difference was found in 
mean arterial blood pressures since dobutamine produced 
a trend toward higher systolic, whereas the milrinone group 
showed a nonsignificant increase of diastolic blood pressure 
(Figs. 2 and 3). Dobutamine as well as milrinone increased 
heart rate similarly in the first postoperative hours (Fig. 4). 
Last, we observed no significant difference in central venous 
So
2
 and lactate levels.
The time to chest tube removal was equal in both groups. 
Ventricular function as measured by repeated transthoracic 
echocardiography was within the normal limits in all patients 
with no difference between the two study groups.
The hemodynamic variables of the four patients with single 
ventricles did not differ significantly from those of patients 
with biventricular repair within the same weight group.
Both drugs were well tolerated, and no serious adverse 
events occurred. No hospital or additional deaths occurred 
during follow-up. In one patient in the dobutamine group, 
renal failure requiring temporary hemodialysis occurred post-
operatively. The occurrence of a low platelet count was similar 
in both groups. Arrhythmias were observed in both groups 
with no preference to either group (Table 1).
TABLE 1. Demographic Data, Operation Characteristics, and Observed Arrhythmias
Study Population Dobutamine Milrinone
n 26 24
Demographics   
 Male, n (%) 13 (50) 15 (63)
 Age at surgery (yr), median (minimum to maximum) 1.7 (0.2–14.2) 0.7 (0.2–11)
 Weight at surgery (kg), median (minimum to maximum) 10.4 (3.8–35) 6.9 (3.4–27.7)
 Down’s syndrome, n 7 6
 Other syndromes, n 2 3
Surgical procedure, n   
 Ventricular septal defect or atrioventricular septal defect closure 13 11
 Left ventricular outflow tract repair 4 3
 Right ventricular outflow tract repair 4 2
 Tetralogy of Fallot repair 2 2
 Fontan completion with extracardiac conduit 1 2
 Pulmonary vein stenosis repair 1 1
 Unifocalization pulmonary arteries in single ventricle  1
 Aortopulmonary window repair  1
 Mitral valve replacement  1
 Anomalous origin of the right coronary artery repair 1  
Perioperative characteristics, median (minimum to maximum)   
 Cardiopulmonary bypass time (min) 126 (73–345) 141 (66–337)
 Aortic cross clamp time (min) 68 (0–143) 63 (0–166)
Adverse events: arrhythmia (total), n 4 7
 AVB III  1  
  Persistent, requiring permanent pacemaker   
  Transient   3
 AVB II type Wenckebach  1  1
 Junctional ectopic tachycardia  1  1
 Supraventricular tachycardia  1  1
 Atrial ectopic tachycardia   1
AVB = atrioventricular block.
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DISCUSSION
To our knowledge, the present study is the first randomized 
double-blind trial comparing dobutamine and milrinone for 
the postoperative prevention or treatment of LCOS in pedi-
atric patients after surgery for congenital heart defects. We 
were able to show that both 
drugs were effective and could 
be safely used in postoperative 
pediatric patients. This find-
ing is in accordance with the 
results of a similar multicenter 
study in adults (6) and a retro-
spective analysis of adult heart 
failure patients (16).
The efficacy of the study 
drug was assessed by compar-
ing the number of patients 
who needed supplementary 
vasoactive support in addition 
to the standardized application 
of the study drugs dobutamine 
or milrinone. Furthermore, we 
compared hemodynamic vari-
ables of LCOS within the first 
48 postoperative hours.
There was no difference in 
the use of additional vasoac-
tive support, which was nec-
essary in 16 patients in each 
group; also, the hemodynamic 
response was similar in both 
study groups. Hence we con-
clude that both drugs (dobu-
tamine and milrinone) are 
equally effective in the preven-
tion of a LCOS in the postop-
erative period after surgery 
for pediatric congenital heart 
defects. Of note, additional 
application of sodium nitro-
prusside due to an increased 
blood pressure was used more 
often in the dobutamine group 
suggesting that milrinone pro-
motes more systemic vasodi-
lation than dobutamine with 
our dose regime.
Exactly the same effect has 
been described previously in 
two adult populations, which 
validates the findings in our 
pediatric population: in a retro-
spective analysis of 329 patients 
with advanced heart failure 
(16) and in a randomized 
open-label multicenter trial 
with 120 adults after cardiac surgery (6), dobutamine compared 
with milrinone was also associated with a higher occurrence rate 
of hypertensive blood pressure. However, the dobutamine doses 
used in the first study were two to three folds higher than ours, 
which may explain the excessive increase of blood pressure.
Figure 2. Systolic blood pressure during the first 48 hr postoperatively. Boxes represent median and 25–75th 
percentile; whiskers represent minimum and maximum.
Figure 3. Diastolic blood pressure during the first 48 hr postoperatively. Boxes represent median and 25–75th 
percentile; whiskers represent minimum and maximum.
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We tried to conduct our study as close as possible to our 
daily routine and local conditions. The patient population and 
the present heart defects reflect the current spectrum in pedi-
atric cardiology with predominantly septal defects in infants. 
Single ventricles constituted 8% of the total cohort (4/50). 
Interestingly, their postoperative performance did not dif-
fer from that of patients with biventricular repair of the same 
group, indicating that both dobutamine and milrinone are 
appropriate medications for this patient group in the man-
agement or prevention of postoperative LCOS. In a double-
blinded randomized study in patients after Fontan completion, 
however, postoperative milrinone was not associated with 
improved early clinical outcome and had to be discontinued in 
a quarter of subjects due to hypotension (17). Even though we 
did not observe relevant hypotension or other adverse events 
in our study cohort, milrinone has to be used with caution in 
single ventricle patients, especially after Fontan completion.
In our study, clinical outcome and complication rates were 
similar in both groups (dobutamine and milrinone). No sig-
nificant differences in the length of mechanical ventilation or 
the ICU stay were detected, and both groups did not have any 
in-hospital or late mortality. Interestingly in this context, there 
is no evidence however about a beneficial effect of milrinone 
on the long-term morbidity and mortality (14, 18).
Arrhythmia has been described as a side effect of dobutamine 
and milrinone. There is conflicting evidence about the extent of 
the arrhythmogenic effect of milrinone. A prospective observa-
tional study of 603 pediatric patients after cardiac surgery found 
that milrinone was independently associated with a nearly 
three-fold increase in the odds 
of a postoperative tachyar-
rhythmia prompting interven-
tion (19). They concluded that 
milrinone is an independent 
risk factor for clinically signifi-
cant tachyarrhythmias in the 
early postoperative period after 
congenital heart surgery. In 
patients after Fontan comple-
tion, arrhythmias were reg-
istered nearly twice as much 
in the milrinone group com-
pared with the placebo group. 
In contrast, in the Primacorp 
trial, arrhythmias were rare 
and occurred with an inci-
dence of only 0.8% (2). In our 
cohort, the overall incidence 
of arrhythmia was low and 
did not differ between the two 
study groups. The occurrence 
of arrhythmia seemed to be 
more related to the type of per-
formed operation than to the 
currently applied medication.
Sinus tachycardia is often 
described as side effect of dobutamine due to its direct action on 
the β-adrenergic receptors and may be dose dependent (20). In 
our study, in both groups heart rates were slightly elevated dur-
ing the whole study period. This might be due to agitation, pain 
or elevated body temperature, which are well-known trigger of 
an elevated heart rate in the postoperative setting. Furthermore 
CPB-triggered inflammation response or postoperative myo-
cardial recovery might also provoke sinus tachycardia.
In our country, a postoperative support with milrinone is 
three to four times more costly than with dobutamine. This 
aspect has also to be taken into account when choosing a medi-
cation in a specific patient.
For practical reasons, the number of participants is rela-
tively small, reducing the statistical power of our study. A fur-
ther limitation is the heterogeneity of the study population 
with regard to their hemodynamics due to the large spectrum 
of congenital heart defects. A mix of diagnoses and operations 
is included, typically seen in pediatric congenital heart surgery; 
therefore, we assume the results are valid and interesting for 
most centers. However, a generalization should be done care-
fully. Furthermore, other drug dose regimes would possibly 
have resulted in different outcomes. For milrinone, we used 
the recommended efficacy dose (2), and for dobutamine, we 
used our house standard dose. The variability of the clinical 
judgment of the responsible intensivist at bedside is another 
possible confounder, which we tried to overcome with clearly 
defined thresholds for the diagnosis of LCOS in a way that 
reflects our current practice. But, it still remains a clear limita-
tion of our study.
Figure 4. Heart rate during the first 48 hr postoperatively. Boxes represent median and 25–75th percentile; 
whiskers represent minimum and maximum.
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We measured and compared urine output, but we did not 
systematically assess fluid intake. Therefore, we cannot make 
a statement about a difference between the study groups in 
the amount of fluid needed to keep the circulation stable. 
Transfusion policy was similar in both groups; hence, we did 
not analyze the use of blood and blood components between 
the groups.
On purpose, we excluded patients younger than 6 weeks 
of age because of ethical reasons, even though this is a rele-
vant and interesting population in pediatric congenital heart 
surgery.
CONCLUSIONS
In our study cohort, dobutamine and milrinone are equally 
effective, safe, and well tolerated for the prevention of a post-
operative LCOS in pediatric patients after cardiovascular sur-
gery. In uncomplicated cases, a trend toward the less expensive 
dobutamine might be anticipated, especially in patients who 
would benefit from a mild increase in blood pressure. In 
patients with the need of profound afterload reduction, mil-
rinone may be advantageous. However, we acknowledge the 
limited power of our pilot trial. Hence, clinical implications 
have to be interpreted with caution. Also, postoperative vaso-
active therapy has to be tailored individually and continuously 
adapted to the specific patient needs, frequently including 
more than one single medication. The knowledge gained from 
our pilot trial has the potential to contribute to the successful 
conduct of future larger scale studies.
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